Investment Rating - The report maintains a positive investment rating for the pharmaceutical industry, emphasizing the importance of supply chain (CXO and upstream sectors) for 2026 [4]. Core Insights - The pharmaceutical industry is expected to enter a prosperous performance phase in 2026, driven by a combination of domestic and international demand recovery and innovation iterations [2]. - The report highlights the strong performance of leading companies in the CXO sector, which are expected to benefit from the recovery of both domestic and international markets [3]. - The report identifies specific investment opportunities in the supply chain, particularly in the CDMO sector, as well as in clinical CRO and safety evaluation sectors, which are anticipated to benefit from the domestic innovation wave [3]. Summary by Sections 1. Supply Chain Focus for 2026 - The CXO industry is in an upward trend, with leading companies demonstrating strong performance and the ability to secure large orders due to their integrated platforms and global presence [13]. - The report notes that the performance of clinical CRO and safety evaluation sectors has shown marginal improvement, with expectations for further performance validation in 2026 [14]. - The report emphasizes the potential for significant growth in the peptide therapy market, predicting a market size of approximately $79.6 billion by 2025, with a compound annual growth rate (CAGR) of nearly 15.8% from 2024 to 2030 [26][29]. 2. Market Review and Hotspot Tracking - The pharmaceutical index experienced a decline of 2.77% from March 16 to March 20, 2026, underperforming compared to the broader market indices [45]. - The report indicates that the pharmaceutical sector's transaction volume was approximately 409.68 billion yuan, accounting for 3.30% of the total market transaction volume [67]. - The report highlights the performance of specific stocks, with notable gains from companies like *ST Jingfeng and Sanofi, while others like Changyao and Xiangyu Medical faced significant declines [71]. 3. Investment Recommendations - The report suggests focusing on three lines in the upstream biotechnology sector: 1) companies benefiting from early-stage innovation trends, 2) companies experiencing recovery in new orders, and 3) leading clinical CRO companies that are expected to gain from the innovation wave [43]. - In the CDMO sector, the report recommends companies with a strong foothold in the peptide supply chain, as well as those positioned to benefit from ADC trends and small nucleic acid developments [43].

Group 1 - The core viewpoint of the article highlights that ST Nuotai (688076.SH) reported its 2025 annual performance, showing a revenue increase but a decline in net profit [1] - The company achieved an operating income of 1.94 billion yuan, representing a year-on-year growth of 19.57% [1] - The net profit attributable to the parent company was 327 million yuan, which reflects a year-on-year decrease of 19.14% [1] Group 2 - The overall sales revenue of the company increased during the reporting period [1] - The decline in gross profit margin was attributed to industry price fluctuations and an increase in fixed costs [1]

Core Viewpoint - ST诺泰 has received approval from the National Medical Products Administration for the drug registration certificate of Ipatasertib, which is indicated for diabetic neuropathy [1] Group 1: Product Information - Ipatasertib is a reversible non-competitive inhibitor of aldose reductase, selectively inhibiting the enzyme [1] - The drug works by inhibiting the accumulation of sorbitol in red blood cells of patients with diabetic peripheral neuropathy, thereby improving patients' subjective symptoms and neurological dysfunction [1]

Group 1 - ST诺泰 announced the receipt of the drug registration certificate for Ipatasertib from the National Medical Products Administration [1] - The approval signifies a significant milestone for 江苏诺泰澳赛诺生物制药股份有限公司 in the pharmaceutical industry [1] Group 2 - The news highlights a shift in AI usage, with China surpassing the US in AI call volume, leading to a surge in various sectors in the A-share market [1] - A notable Wall Street analyst commented on China's computing power path, indicating a disruption of traditional perceptions [1]

证券代码：688076 证券简称：ST 诺泰 公告编号：2026-011 （一）资产减值损失 公司对固定资产、无形资产等长期资产，在资产负债表日有迹象表明发生减 江苏诺泰澳赛诺生物制药股份有限公司 关于 2025 年度计提资产减值准备的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据《企业会计准则》以及江苏诺泰澳赛诺生物制药股份有限公司（以下简 称"公司"）的会计政策、会计估计的相关规定，为了真实、准确地反映公司截 至2025年12月31日的财务状况和2025年度的经营成果，本着谨慎性原则，公司对 截至2025年12月31日公司及子公司的资产进行了减值测试，对存在减值迹象的资 产相应计提了减值准备，现将有关事项公告如下： 一、计提资产减值准备情况概述 2025年，公司计提资产减值准备总额为-9,189.23万元（损失以"-"号填列）。 具体情况如下表所示： 单位：万元 | 序号 | 项目 | 2025年计提金额 | 备注 | | --- | --- | --- | --- | | 1 | 信用减值损失（损失以 | - ...

Financial Performance - In 2025, the company achieved total operating revenue of CNY 1,942,799,144.82, representing a year-on-year increase of 19.57%[5] - The net profit attributable to the parent company was CNY 326,999,932.94, a decrease of 19.14% compared to the previous year[5] - The net profit attributable to the parent company after deducting non-recurring gains and losses was CNY 363,931,382.12, down 10.76% year-on-year[5] - The company's basic earnings per share decreased by 20.61% to CNY 1.04[5] - The weighted average return on net assets decreased by 5.65 percentage points to 11.28%[5] Assets and Equity - The company's total assets at the end of 2025 were CNY 6,733,330,456.35, an increase of 32.60% from the beginning of the year[5] - The equity attributable to the parent company increased by 11.86% to CNY 2,975,857,619.45 compared to the beginning of the year[5] - The company's share capital increased by 43.80% to CNY 316,051,897.00, primarily due to the conversion of capital reserves into share capital[12] Operational Challenges - The overall sales revenue growth was impacted by industry price fluctuations and increased fixed costs, leading to a decline in gross profit margin[10] - The company conducted impairment testing on certain assets, which affected the current period's performance[10]

江苏诺泰澳赛诺生物制药股份有限公司 关于自愿披露依帕司他片获得药品注册证书的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 江苏诺泰澳赛诺生物制药股份有限公司（以下简称"公司"或"诺泰生物"） 于近日收到国家药品监督管理局核准签发的依帕司他片的《药品注册证书》（证 书编号：2026S00470），现将相关情况公告如下： 一、《药品注册证书》的主要内容 药品名称：依帕司他片 证券代码：688076 证券简称：ST 诺泰 公告编号：2026-009 生产企业：江苏诺泰澳赛诺生物制药股份有限公司 药品批准文号：国药准字 H20263399 药品批准文号有效期：至 2031 年 02 月 09 日 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册，发给药品注册证书。质量标准、说明书、 剂型：片剂 规格：50mg 申请事项：药品注册（境内生产） 注册分类：化学药品 3 类 药品有效期：18 个月 包装规格：10 片/板，1 板/盒 上市许可持有人：江苏诺泰澳赛诺生物制药股份有限 ...

Investment Rating - The report maintains a "Recommended" rating for the pharmaceutical industry [5] Core Insights - The underlying logic of the current pharmaceutical industry era is innovation and international expansion, with a focus on innovative drugs and technology-driven sectors [2][3] - The report highlights the strong performance of the CRO market and suggests a dual investment strategy focusing on both "0 to 1" technology innovation and low-position stocks [2][3] - The report emphasizes the ongoing trend of BD (Business Development) transactions in innovative drugs, with significant growth expected in 2026 [4][15] Summary by Sections 1. Key Events in the Pharmaceutical Industry During the Spring Festival - Innovative drug BD transactions have seen a strong start, with significant overseas development and registration progress for key products [13][14] - The total amount of BD transactions for innovative drugs in China for 2026 has already surpassed one-third of the total for 2025 [15] - The revision of the National Essential Medicines List Management Measures may signal changes in the essential medicines directory [28] 2. Pharmaceutical Market Review and Hotspot Tracking - The pharmaceutical sector's performance was relatively weak, with a weekly decline of 0.81%, ranking 20th among all industries [34][38] - The total trading volume for pharmaceuticals was 401.12 billion yuan, accounting for 3.83% of the total market, below the historical average of 7.09% [55] - The report notes a rising valuation level for the pharmaceutical industry, with a PE ratio of 29.25, which is below the historical average [52] 3. Stock Performance Review - The report lists the top-performing stocks, including Dongyangguang and Zhendemedical, while highlighting the underperformers like Huayuan Biology and *ST Sailong [58][59]

Group 1 - The core issue involves investor claims against Nuotai Bio (688076) due to false statements leading to ongoing legal proceedings [1][5] - The Shanghai Financial Court has accepted the case for investor claims against Nuotai Bio, with further claims being processed [1][5] - Nuotai Bio's 2021 annual report was found to contain false records, including a reported revenue of 30 million yuan from a technology transfer that lacked commercial substance, inflating total revenue by 30 million yuan and profit by 25.95 million yuan, which accounted for 20.64% of the reported profit [1][5] Group 2 - Investors who purchased Nuotai Bio shares between April 28, 2022, and October 24, 2024, and sold or held shares after October 24, 2024, are eligible to file claims [2][6] - The law firm is also handling claims for Century Huatong (002602), with a recent filing submitted to the Shaoxing Intermediate People's Court [2][6] - Century Huatong was found to have false records in its annual reports from 2018 to 2022, including fabricated software copyright transfer transactions and premature revenue recognition [3][7] Group 3 - Investors who bought Century Huatong shares between April 27, 2019, and July 25, 2023, and sold or held shares after July 25, 2023, can initiate claims [4][8] - The law firm has a history of successfully representing investors in similar cases, with many having received compensation [4][8]

Core Viewpoint - ST诺泰's subsidiary, Hangzhou Ausino Biotechnology Co., Ltd., has successfully passed the GMP compliance inspection for its active pharmaceutical ingredient, Aogetwei Sodium, marking a significant milestone in its production capabilities [1] Group 1: Company Achievements - The company received the GMP compliance inspection notice from the Zhejiang Provincial Drug Administration, indicating its adherence to high production and quality management standards [1] - The successful inspection of the raw material production line at the Jiande factory reinforces the company's commitment to leading in both time and technology [1] Group 2: Business Implications - This achievement is pivotal for the company's CDMO (Contract Development and Manufacturing Organization) business, allowing it to extend its value from advanced intermediates to active pharmaceutical ingredients [1] - The milestone is expected to positively impact the company's efforts in expanding its client base for innovative pharmaceutical raw materials [1]